Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-Current Deferred Tax Liability (2018 - 2020)

Zevra Therapeutics (ZVRA) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $540000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Non-Current Deferred Tax Liability rose 5300.0% year-over-year to $540000.0, compared with a TTM value of $540000.0 through Dec 2019, up 5300.0%, and an annual FY2019 reading of $540000.0, up 5300.0% over the prior year.
  • Non-Current Deferred Tax Liability was $540000.0 for Q4 2019 at Zevra Therapeutics, up from $10000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $540000.0 in Q4 2019 and bottomed at $10000.0 in Q4 2018.